A Single-Arm Phase II Clinical Trial of Cabozantinib (XL184) in Patients With Previously Treated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases With and Without C Met Amplification

Trial Profile

A Single-Arm Phase II Clinical Trial of Cabozantinib (XL184) in Patients With Previously Treated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases With and Without C Met Amplification

Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Aug 2018

At a glance

  • Drugs Cabozantinib (Primary)
  • Indications Brain metastases; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Jul 2018 Planned End Date changed from 1 Jun 2028 to 1 Jul 2024.
    • 30 Jul 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Jul 2019.
    • 13 Jan 2016 Planned End Date changed from 1 Dec 2027 to 1 Jun 2028 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top